No differences in drug levels or disease activity were found when adult patients with inflammatory bowel disease (IBD) were switched from originator infliximab (Remicade) to a biosimilar infliximab (Inflectra) as part of routine care, according to the results of a Dutch study.
No differences in drug levels or disease activity were found when adult patients with inflammatory bowel disease (IBD) were switched from originator infliximab (Remicade) to a biosimilar infliximab (Inflectra) as part of routine care, according to the results of a Dutch study published in Alimentary Pharmacology & Therapeutics. Switching to the biosimilar and performing therapeutic drug monitoring as part of routine care optimizes infliximab therapy efficiently and makes it more cost effective, the authors conclude.
The study, conducted by E.M.H. Schmitz, PhD, and colleagues, followed 133 patients with IBD (64% had Crohn’s disease [CD]; 36% had ulcerative colitis [UC]) for 12 months. All patients had been receiving innovator infliximab therapy for a median of 52 months before the switch to biosimilar. Half of the patients received concomitant immunosuppressive therapy. The researchers took blood samples just before the first, second, fourth, and seventh infusion of the biosimilar and measured infliximab trough levels, antibodies to infliximab (ATI), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR). The investigators also calculated disease activity scores using the Crohn’s disease activity index for patients with CD and the Truelove-Witts disease activity index for patients with UC.
Before the switch to biosimilar infliximab, the investigators found widely varying infliximab levels (median, 3.5µg per mL). ATI were detected in 6% of patients. Most patients were in remission or had mild disease (CD, 82%; UC, 90%). After switching to the biosimilar, 26% of patients (26% CD; 27% UC) discontinued therapy within 12 months, mostly because of subjective higher disease activity (9%) and adverse events (AEs, 9.8%). AEs included general malaise and fatigue, arthralgia, skin problems, and infusion reactions. There were no differences in levels of infliximab or CRP or disease activity between the 4 time points (P ≥0.0917).
Nine percent of the cohort experienced higher disease activity. In the majority of cases, however, complaints of higher disease activity were not shown objectively with higher disease activity scores or increased CRP levels. Increased disease activity was only shown objectively in 2 patients.
In 2 cases, patients also had high disease activity on infliximab innovator therapy. Finally, 3.8% of the cohort discontinued biosimilar therapy because they were in remission, 1 patient temporarily stopped infliximab therapy because she was expecting to go into labor, and 2 patients accidently received innovator instead of biosimilar infliximab.
The researchers said that they found that patients with detectable ATI before switching had a relative risk of 3.2 for discontinuation of biosimilar therapy compared with patients with no ATI. “This indicates that patients with autoimmune response to [infliximab] have a statistically significantly higher risk of therapy failure,” they note. “It was shown that antibodies to [infliximab] innovator are highly similar to antibodies to the biosimilar, so these patients would probably also have experienced therapy failure if they would have stayed on innovator therapy.”
The researchers also said that the novelty of biosimilars could induce the nocebo effect (disease worsening due to negative expectations) and noted that the switch to biosimilars was the first such switch in their hospital. “Patients were easily put back on innovator treatment if they had complaints that could possibly be switch-related due to the lack of experience with biosimilars in clinical practice,” they said.
The researchers conclude that biosimilar infliximab is safe and effective. They said the high proportion of discontinuers in their study were mostly due to elective withdrawal or subjective disease worsening.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Patient-Reported Outcomes Similar Between Adalimumab-adbm, Reference Product in VOLTAIRE-RA Study
September 28th 2024A summary of research written by Vibeke Strand, MD, clinical professor in division of immunology/rheumatology at Stanford University School of Medicine, gave an overview of patient-reported outcomes (PROs) in the VOLTAIRE-RA trial.
Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition
June 2nd 2024On this episode of Not So Different, we review the biggest gastroenterology biosimilar stories from May 2024, covering new data from conferences and journals on infliximab and adalimumab products that demonstrate positive clinical results and confirm the safety of these biosimilars, as well as the feasibility of switching to them.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.
French Study Finds High Patient Satisfaction With Adalimumab Biosimilar Treatment for IBD
September 21st 2024An observational study assessing patient satisfaction with adalimumab for inflammatory bowel disease (IBD) reported a high level of satisfaction with all adalimumab product, including biosimilars.